FTX 005778
Alternative Names: FTX-005778Latest Information Update: 27 Sep 2024
At a glance
- Originator Fountain Therapeutics
- Class Antineoplastics; Obesity therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lipodystrophy; Obesity
- Discontinued Solid tumours
Most Recent Events
- 04 Sep 2024 Discontinued - Phase-III for Solid tumours (unspecified route) (Fountain Therapeutics pipeline, September 2024)
- 04 Sep 2024 Phase-III clinical trials in Solid tumours (unspecified route) prior to September 2024 (Fountain Therapeutics pipeline, September 2024)
- 04 Sep 2024 Preclinical trials in Lipodystrophy in USA (PO) prior to September 2024 (Fountain Therapeutics pipeline, September 2024)